A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients

Tropical Medicine and International Health

Volumn 12, Issue 10, 2007, Pages 1191-1198

  Etard, Jean François ^a,b   Lanièce, Isabelle ^c   Fall, Mame Basty Koita ^d   Cilote, Vannina ^c   Blazejewski, Laure ^e,f   Diop, Karim ^g   Desclaux, Alice ^h,i   Ecochard, René ^e,f   Ndoye, Ibra ^j   Delaporte, Eric ^a,b   Ndoye, I ^j   Delaporte, E ^a,b   Etard, J F ^a,b   Laurent, C ^a,b   Taverne, B ^a,b   Basty Fall, M ^d   Dieng, A B ^d   Diouf, A ^d   Massidi, C ^d   Sarr, A ^d   Sow, K ^d   Zie L ^d   Cilote, V ^c   Laniece I ^c   Ndiaye, I ^d   Ndour, C T ^d   Sow, P S ^d   Ngom Gueye N F ^d   Ba Fall, K ^k   Gueye P M ^k   Diaw, P A ^d   Diop Ndiaye, H ^d   Mboup, S ^d   Toure Kane N C ^d   Diop, K ^g   Ndiaye, B ^l   Desclaux, A ^h,i   more..

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b UNIV MONTPELLIER   (France)

^c Ambassade de France   (Senegal)

^d Centre Hospitalier Universitaire Dakar   (Senegal)

^e HOSPICES CIVILS DE LYON   (France)

^f UNIVERSITÉ LYON 1   (France)

^g MINISTÈRE DE LA SANTÉ   (Senegal)

^h AIX MARSEILLE UNIVERSITY   (France)

ⁱ Institut de Formation en Ecologie Humaine et Anthropologie   (France)

^j Secrétariat Exécutif du Conseil National de Lutte contre le Sida   (Senegal)

^k Hopital Pricipal de Dakar   (Senegal)

^l Centre Hospitalier National Universitaire de Fann   (Senegal)

more..

Author keywords

Highly active antiretroviral therapy; Human immunodeficiency virus; Patient compliance; Senegal

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; COHORT ANALYSIS; COMPLIANCE; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS; INHIBITOR;

ADULT; AMBULATORY CARE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACIST; PRACTICE GUIDELINE; PRESCRIPTION; QUESTIONNAIRE; SENEGAL; TABLET; TREATMENT DURATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUESTIONNAIRES; SENEGAL;

AFRICA; SENEGAL; SUB-SAHARAN AFRICA; WEST AFRICA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 35448999726     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2007.01910.x     Document Type: Article

References (35)

1. Attaran A (2007) Adherence to HAART: Africans take medicines more faithfully than North Americans. PLoS Medicine 4, e83.
2. Bangsberg DR, Perry S, Charlebois ED et al. (2001) Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15, 1181 1183.
3. Bova CA, Fennie KP, Knafl GJ, Dieckhaus KD, Watrous E Williams AB (2005) Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav. Mar 9, 103 110.
4. Carrieri MP, Leport C, Protopopescu C et al. (2006) Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. Journal of Acquired Immune Deficiency Syndromes 41, 477 485.
5. CDC (1992) 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report 41(RR-17), 1.
6. Christensen AJ (2004) Patient Adherence to Medical Treatment Regimens: Bridging the Gap between Behavioral Science and Biomedicine. Yale University Press, New Heaven and London.
7. Costagliola D Barberousse C (2001) Comment mesurer l'observance?. In : L'observance aux traitements contre le VIH/sida : mesure, déterminants, évolution. Collection sciences sociales et sida (eds D Bessette, M Bungener, D Costagliola, YA Floric, S Matheron, M Morin, M Setbon Y Souteyrand). ANRS, Paris, pp. 33 42.
8. Crane JT, Kawuma A, Oyugi JH et al. (2006) The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala,Uganda. AIDS Behav 10, 437 442.
9. Desclaux A, Ciss M, Taverne B et al. (2003) Access to antiretroviral drugs and AIDS management in Senegal. AIDS 17 (Suppl 3 S95 S101.
10. Desclaux A, Lanièce I, Ndoye I Taverne B (2004) The Senegalese Antiretroviral Drug Access Initiative. An economic, social, behavioural and biomedical analysis. ANRS, UNAIDS, WHO, Paris.
11. Etard JF, Ndiaye I, Thierry-Mieg M et al. (2006) Mortality and causes of death in adults receiving HAART in Senegal: a 7-year cohort study. AIDS 20, 1181 1189.
12. Ferradini L, Jeannin A, Pinoges L et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367, 1335 1342.
13. Gill CJ, Hamer DH, Simon JL, Thea DM Sabin LL (2005) No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS 19, 1243 1249.
14. Kerr T, Walsh J, Lloyd-Smith E Wood E (2005) Measuring adherence to highly active antiretroviral therapy: implications for research and practice. Curr HIV/AIDS Rep 2, 200 205.
15. Lanièce I, Ciss M, Desclaux A et al. (2003) Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 17 (suppl 3 S103 S108.
16. Maggiolo F, Ravasio L, Ripamonti D et al. (2005) Similar adherence rates favour different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitor. Clinical Infectious Diseases 40, 164 166.
17. Mills EJ, Nachega JB, Buchan I et al. (2006) Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296, 679 690.
18. Müller O, Corrah T, Katabira E, Plummer F Mabey D (1998) Antiretroviral therapy in sub-Saharan Africa. Lancet 351, 68.
19. Nieuwkerk PT Oort FJ (2005) Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. Journal of Acquired Immune Deficiency Syndromes 38, 445 448.
20. Orrell C (2005) Antiretroviral adherence in a resource-poor setting. Curr HIV/AIDS Rep 2, 171 176.
21. Orrell C, Bangsberg DR, Badri M Wood R (2003) Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 17, 1369 1375.
22. Oyugi JH, Byakika-Tusiime J, Charlebois ED et al. (2004) Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. Journal of Acquired Immune Deficiency Syndromes 36, 1100 1102.
23. Paterson DL, Swindell S, Mohr J et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 133, 21 30.
24. République du Sénégal (2001) Plan stratégique 2002-2006 de lutte contre le SIDA. Conseil National de Lutte contre le SIDA, Dakar.
25. République du Sénégal (2006) Données épidémiologiques du VIH/SIDA au Sénégal, 2004-2005. Conseil National de Lutte contre le Sida; Ministère de la santé et de la prévention médicale, Division de Lutte contre le Sida/IST; CHU Le Dantec, Laboratoire de Bactériologie et de Virologie, Dakar.
26. Rubio M, Pedeboscq S, Ekouevi D et al. (2005) The adherence to antiretroviral treatment evaluated from a hospital pharmacy: importance of the protease inhibitors pharmacological class. International Journal of STD and AIDS 16, 379 382.
27. Salmon-Ceron D, Deleuze J, Coste J et al. (2000) Enquête sur l'observance des traitements antirétroviraux comportant un inhibiteur de protéase chez les patients infectés par le VIH. Ann Med Int 151, 297 302.
28. Spire B (2003) Observance au traitement antiretroviral. In : VIH Edition 2004 (eds PM Girard, C Katalama G Pialoux). Doin, Paris, p. 351 357.
29. Spire B, Duran S, Souville M et al. (2001) L'observance aux multithérapies des personnes infectées par le VIH : de l'approche prédictive à l'approche dynamique. In : L'observance aux traitements contre le VIH/sida : mesure, déterminants, évolution. Collection sciences sociales et sida (eds D Bessette, M Bungener, D Costagliola, YA Floric, S Matheron, M Morin, M Setbon Y Souteyrand) ANRS, Paris, pp. 43 56.
30. UNAIDS (2007) Epidemiological Software and Tools. Available at: http://www.unaids.org/en/HIV_data/Epidemiology/episoftware2007.asp.
31. UNAIDS (2006) United the World against AIDS. Available at : http://www.unaids.org/en/Regions_Countries/Countries/senegal.asp.
32. Weidle PJ, Wamai N, Solberg P et al. (2006) Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 368, 1587 1594.
33. Weiser S, Wolfe W, Bangsberg D et al. (2003) Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal of Acquired Immune Deficiency Syndromes 34, 281 288.
34. World Health Organization (2003) Adherence to Long-term Therapies: Evidence for Action. WHO, Geneva pp. 95 106.
35. World Health Organization (2006) Global Health Atlas Available at: http://www.who.int/GlobalAtlas/.